A Phase II Placebo-Controlled Trial of Cannabidivarin (CBDV) in Patients with Rett Syndrome
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
Price : $35 *
At a glance
- Drugs Cannabidivarin (Primary)
- Indications Rett syndrome
- Focus Therapeutic Use
- 05 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jul 2018, according to a GW Pharmaceuticals media release.
- 05 Feb 2018 According to a GW Pharmaceuticals media release, this trial is due to commence in Q3 2018.
- 17 May 2017 New trial record